CervoMed (NASDAQ:CRVO – Get Free Report) was upgraded by equities research analysts at Chardan Capital to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports. D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. Get CervoMed alerts:Check Out Our Latest Stock Report on CRVOCervoMed Stock Up 0.4%CervoMed stock opened at $2.81 on Monday. AQR Capital Management LLC bought a new position in shares of CervoMed during the 1st quarter valued at approximately $227,000. CervoMed Company Profile(Get Free Report)CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.